Please ensure Javascript is enabled for purposes of website accessibility

Why Haemonetics Stock Dived by 15% Today

By Eric Volkman – Nov 9, 2021 at 6:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company broadly meets expectations for its Q2 2022 but trims its full-year guidance.

What happened

Haemonetics (HAE -3.09%) had a day to forget on Tuesday. Following the release of its latest quarterly earnings, the blood and plasma collection specialist's stock fell by over 15%.

So what

Haemonetics booked revenue of $240 million for its second quarter of fiscal 2022, which was 15% higher on a year-over-year basis. Going in the opposite direction, but not alarmingly so, was non-GAAP (adjusted) net income. This dipped by 3% compared to the year-ago period to land at $30.7 million, or $0.60 per share.

Old and young male patients seated and conferring with a doctor.

Image source: Getty Images.

Both of those results are more or less in line with expert projections. Collectively, analysts following the company were estimating it would take in $239.99 million in revenue and $0.61 per share in adjusted net profit.

Previously, Haemonetics had been affected by a general trend in patients delaying elective medical procedures and the resulting dip in demand for its services. The situation is improving, however.

"While we encountered a delay in the acceleration of plasma collections in the quarter, we did see encouraging signs of recovery and our Hospital and Blood Center businesses delivered strong sales despite the resurgence of COVID-19," the healthcare company quoted CEO Chris Simon as saying.

Now what

Simon added that Haemonetics should see "additional growth" in those crucial areas for the company in the remainder of this fiscal year. However, it did trim its generally accepted accounting principles (GAAP) revenue guidance for the entirety of fiscal 2022. It now believes its top line will expand 7% to 10% on an annual basis, down from its previous forecast of 8% to 12%.

While that's disappointing, it's hardly sufficient justification for a double-digit sell-off. Haemonetics bulls should not be discouraged by this knee-jerk reaction from the market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.